Details of Drug

Drug General Information (ID: D0260)
Drug Name	Carboplatin
Drug Type	Small molecule
Drug Synonymous	Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II) Click to Show/Hide
Disease Class	2C73: Ovarian cancer
Therapeutic Class	Antineoplastics
Structure
Structure	3D Structure		2D Structure
Formula	C6H12N2O4Pt
InChI	1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);21H2;/q;2-1;+2
InChIKey	VSRXQHXAPYXROS-UHFFFAOYSA-N
Canonical SMILES	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
External Link
	Pubchem ID	426756
	CAS Number	41575-94-4
	CHEBI ID	31355
	TTD ID	D0X7HM
	INTEDE ID	DR0272
	VARIDT ID	DR00469

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM006 Altered intestinal mucosa BM013 Competitive binding of plasma proteins BM027 Decreased renal excretion due to nephrotoxicity BM043 Additive immunosuppressive effects BM044 Additive myelosuppressive effects BM047 Additive thrombogenic effects BM066 Increased risk of hypomagnesemia BM072 Increased risk of nephrotoxicity BM073 Increased risk of ototoxicity BM074 Increased risk of peripheral neuropathy BM100 Antagonize the effect of vaccine/toxoid BM105 Antagonize the effect of probiotics BM106 Diminish the response to diagnostic skin test antigens BM107 Attenuated pharmacological effects (Unspecific) BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Carboplatin
Affected gastrointestinal absorption
	Altered intestinal mucosa					Drug Num: 14
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Minor		Inter Info	[125]
D0712		Gatifloxacin	C19H22FN3O4	5379	Minor		Inter Info	[125]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Minor		Inter Info	[125]
D0919		Levofloxacin	C18H20FN3O4	149096	Minor		Inter Info	[125]
D0943		Lomefloxacin	C17H19F2N3O3	3948	Minor		Inter Info	[125]
D1155		Norfloxacin	C16H18FN3O3	4539	Minor		Inter Info	[125]
D1165		Ofloxacin	C18H20FN3O4	4583	Minor		Inter Info	[125]
D1499		Sparfloxacin	C19H22F2N4O3	60464	Minor		Inter Info	[125]
D0340		Cinoxacin	C12H10N2O5	2762	Minor		Inter Info	[125]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Minor		Inter Info	[125]
D0573		Enoxacin	C15H17FN4O3	3229	Minor		Inter Info	[125]
D0740		Grepafloxacin	C19H22FN3O3	72474	Minor		Inter Info	[125]
D1102		Nalidixic acid	C12H12N2O3	4421	Minor		Inter Info	[125]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Minor		Inter Info	[125]
Affected organization distribution
	Competitive binding of plasma proteins					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0087		Anisindione	C16H12O3	2197	Moderate		Inter Info	[74], [75]
D0481		Dicoumarol	C19H12O6	54676038	Moderate		Inter Info	[112], [74], [75]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[74], [75]
Affected excretion pathways
	Decreased renal excretion due to nephrotoxicity					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1389		Remdesivir	C27H35N6O8P	121304016	Moderate		Inter Info	[10], [11], [104], [105], [106]
Pharmacodynamic additive effects
	Additive immunosuppressive effects					Drug Num: 75
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0023		Adalimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0146		Baricitinib	C16H17N7O2S	44205240	Major		Inter Info	[10], [11], [12]
D0304		Certolizumab pegol	NA	NA	Major		Inter Info	[1], [5], [6]
D0661		Fingolimod	C19H33NO2	107970	Major		Inter Info	[15]
D0736		Golimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0900		Leflunomide	C12H9F3N2O2	3899	Major		Inter Info	[17], [18]
D1211		Ozanimod	C23H24N4O3	52938427	Major		Inter Info	[11], [19]
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[10], [21]
D1556		Teriflunomide	C12H9F3N2O2	54684141	Major		Inter Info	[17], [18]
D1575		Thiotepa	C6H12N3PS	5453	Major		Inter Info	[40]
D1600		Tofacitinib	C16H20N6O	9926791	Major		Inter Info	[41]
D1666		Upadacitinib	C17H19F3N6O	58557659	Major		Inter Info	[45]
D0348		Cladribine	C10H12ClN5O3	20279	Major		Inter Info	[11], [47]
D0614		Etanercept	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0802		Infliximab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D1111		Natalizumab	NA	NA	Major		Inter Info	[50]
D0030		Aldesleukin	NA	NA	Moderate		Inter Info	[11], [54], [55]
D0032		Alefacept	NA	NA	Moderate		Inter Info	[22], [56], [57]
D0033		Alemtuzumab	NA	NA	Moderate		Inter Info	[58]
D0085		Anakinra	C20H23N5O7S2	146171046	Moderate		Inter Info	[60], [61], [62]
D0190		Bleomycin	C55H84N17O21S3+	5360373	Moderate		Inter Info	[11], [54], [55]
D0136		Azathioprine	C9H7N7O2S	2265	Moderate		Inter Info	[10], [11]
D0157		Bendamustine	C16H21Cl2N3O2	65628	Moderate		Inter Info	[11], [54], [55]
D0223		Busulfan	C6H14O6S2	2478	Moderate		Inter Info	[11], [54], [55]
D0246		Canakinumab	NA	NA	Moderate		Inter Info	[60], [61], [62]
D0249		Capecitabine	C15H22FN3O6	60953	Moderate		Inter Info	[11], [54], [55]
D0404		Cytarabine	C9H13N3O5	6253	Moderate		Inter Info	[11], [54], [55]
D0405		Cytarabine (liposomal)	C9H13N3O5	6253	Moderate		Inter Info	[11], [54], [55]
D0410		Dactinomycin	C62H86N12O16	457193	Moderate		Inter Info	[11], [54], [55]
D0431		Decitabine	C8H12N4O4	451668	Moderate		Inter Info	[11], [54], [55]
D0443		Denosumab	NA	NA	Moderate		Inter Info	[86]
D0499		Dimethyl fumarate	C6H8O4	637568	Moderate		Inter Info	[88]
D0507		Diroximel fumarate	C11H13NO6	73330464	Moderate		Inter Info	[88]
D0528		Doxorubicin	C27H29NO11	31703	Moderate		Inter Info	[11], [54], [55]
D0529		Doxorubicin (liposomal)	C27H29NO11	31703	Moderate		Inter Info	[11], [54], [55]
D0780		Hydroxyurea	CH4N2O2	3657	Moderate		Inter Info	[11], [54], [55]
D0788		Idarubicin	C26H27NO9	42890	Moderate		Inter Info	[11], [54], [55]
D0790		Ifosfamide	C7H15Cl2N2O2P	3690	Moderate		Inter Info	[11], [54], [55]
D0851		Isatuximab	NA	NA	Moderate		Inter Info	[11], [54], [55]
D0945		Lomustine	C9H16ClN3O2	3950	Moderate		Inter Info	[11], [54], [55]
D0962		Lurbinectedin	C41H44N4O10S	57327016	Moderate		Inter Info	[11], [54], [55]
D0996		Melphalan	C13H18Cl2N2O2	460612	Moderate		Inter Info	[11], [54], [55]
D1007		Mercaptopurine	C5H4N4S	667490	Moderate		Inter Info	[11], [54], [55]
D1079		Mitoxantrone	C22H28N4O6	4212	Moderate		Inter Info	[11], [54], [55]
D1085		Monomethyl fumarate	C5H6O4	5369209	Moderate		Inter Info	[88]
D1140		Niraparib	C19H20N4O	24958200	Moderate		Inter Info	[92]
D1162		Ocrelizumab	NA	NA	Moderate		Inter Info	[93]
D1167		Olaparib	C24H23FN4O3	23725625	Moderate		Inter Info	[11], [94]
D1174		Omacetaxine mepesuccinate	C29H39NO9	285033	Moderate		Inter Info	[95]
D1375		Radium Ra 223 dichloride	NA	NA	Moderate		Inter Info	[103]
D1403		Rilonacept	NA	NA	Moderate		Inter Info	[60], [61], [62]
D1422		Roflumilast	C17H14Cl2F2N2O3	449193	Moderate		Inter Info	[11], [107]
D1487		Sodium phosphate, monobasic (p32)	NA	NA	Moderate		Inter Info	[108]
D1509		Strontium chloride Sr-89	Cl2Sr	5388879	Moderate		Inter Info	[10], [11], [109]
D1671		Ustekinumab	NA	NA	Moderate		Inter Info	[110]
D0264		Carmustine	C5H9Cl2N3O2	2578	Moderate		Inter Info	[11], [54], [55]
D0306		Cetuximab	NA	NA	Moderate		Inter Info	[10], [11]
D0312		Chlorambucil	C14H19Cl2NO2	2708	Moderate		Inter Info	[11], [54], [55]
D0400		Cyclophosphamide	C7H15Cl2N2O2P	2907	Moderate		Inter Info	[11], [54], [55]
D0407		Dacarbazine	C6H10N6O	135398738	Moderate		Inter Info	[11], [54], [55]
D0429		Daunorubicin	C27H29NO10	30323	Moderate		Inter Info	[11], [54], [55]
D0430		Daunorubicin (liposomal)	C27H29NO10	30323	Moderate		Inter Info	[11], [54], [55]
D0553		Efalizumab	NA	NA	Moderate		Inter Info	[113]
D0584		Epirubicin	C27H29NO11	41867	Moderate		Inter Info	[11], [54], [55]
D0675		Fluorouracil	C4H3FN2O2	3385	Moderate		Inter Info	[11], [54], [55]
D0714		Gemcitabine	C9H11F2N3O4	60750	Moderate		Inter Info	[11], [54], [55]
D0793		Imatinib	C29H31N7O	5291	Moderate		Inter Info	[11], [54], [55]
D0986		Mechlorethamine	C5H11Cl2N	4033	Moderate		Inter Info	[11], [54], [55]
D1077		Mitomycin	C15H18N4O5	5746	Moderate		Inter Info	[11], [54], [55]
D1855		Palifermin	NA	NA	Moderate		Inter Info	[119]
D1241		Pemetrexed	C20H21N5O6	135410875	Moderate		Inter Info	[11], [54], [55]
D1250		Pentostatin	C11H16N4O4	439693	Moderate		Inter Info	[11], [54], [55]
D1508		Streptozocin	C8H15N3O7	29327	Moderate		Inter Info	[11], [54], [55]
D1589		Tioguanine	C5H5N5S	2723601	Moderate		Inter Info	[11], [54], [55]
D1720		Zidovudine	C10H13N5O4	35370	Moderate		Inter Info	[10], [11], [124]
	Additive myelosuppressive effects					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0433		Deferiprone	C7H9NO2	2972	Major		Inter Info	[10], [13], [14]
D1443		Samarium (153Sm) lexidronam	Sm	23951	Major		Inter Info	[20]
D1610		Topotecan	C23H23N3O5	60700	Major		Inter Info	[42], [43], [44]
D0370		Clozapine	C18H19ClN4	135398737	Major		Inter Info	[11], [48], [49]
D0710		Ganciclovir	C9H13N5O4	135398740	Moderate		Inter Info	[10], [11], [89], [90]
D1676		Valganciclovir	C14H22N6O5	135413535	Moderate		Inter Info	[10], [11], [89], [90]
	Additive thrombogenic effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Major		Inter Info	[24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39]
	Increased risk of hypomagnesemia					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0458		Dexlansoprazole	C16H14F3N3O2S	9578005	Moderate		Inter Info	[87]
D1373		Rabeprazole	C18H21N3O3S	5029	Moderate		Inter Info	[87]
D0603		Esomeprazole	C17H19N3O3S	9568614	Moderate		Inter Info	[87]
D0892		Lansoprazole	C16H14F3N3O2S	3883	Moderate		Inter Info	[87]
D1179		Omeprazole	C17H19N3O3S	4594	Moderate		Inter Info	[87]
D1222		Pantoprazole	C16H15F2N3O4S	4679	Moderate		Inter Info	[87]
	Increased risk of nephrotoxicity					Drug Num: 14
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0805		Inotersen	C230H318N69O121P19S19	121492004	Major		Inter Info	[11], [16]
D0335		Cidofovir	C8H14N3O6P	60613	Major		Inter Info	[46]
D0056		Amikacin	C22H43N5O13	37768	Moderate		Inter Info	[59]
D0057		Amikacin (liposome)	C22H43N5O13	37768	Moderate		Inter Info	[59]
D0252		Capreomycin	C50H88N28O15	3000502	Moderate		Inter Info	[10], [70], [71]
D0876		Kanamycin	C18H36N4O11	6032	Moderate		Inter Info	[59]
D1120		Neomycin	C23H46N6O13	8378	Moderate		Inter Info	[59]
D1507		Streptomycin	C21H39N7O12	19649	Moderate		Inter Info	[59]
D0357		Clofarabine	C10H11ClFN5O3	119182	Moderate		Inter Info	[111]
D0718		Gentamicin	C21H43N5O7	3467	Moderate		Inter Info	[59]
D1126		Netilmicin	C21H41N5O7	441306	Moderate		Inter Info	[59]
D1597		Tobramycin	C18H37N5O9	36294	Moderate		Inter Info	[59]
D1672		Valaciclovir	C13H20N6O4	135398742	Moderate		Inter Info	[11], [122]
D1680		Vancomycin	C66H75Cl2N9O24	14969	Moderate		Inter Info	[10], [70], [71]
	Increased risk of ototoxicity					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0217		Bumetanide	C17H20N2O5S	2471	Moderate		Inter Info	[10], [11], [66], [67], [68], [59], [69]
D0613		Etacrynic acid	C13H12Cl2O4	3278	Moderate		Inter Info	[66], [114], [59]
D0704		Furosemide	C12H11ClN2O5S	3440	Moderate		Inter Info	[10], [11], [66], [67], [68], [59], [69]
D1611		Torasemide	C16H20N4O3S	41781	Moderate		Inter Info	[66], [114], [59]
	Increased risk of peripheral neuropathy					Drug Num: 70
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0193		Bortezomib	C19H25BN4O4	387447	Moderate		Inter Info	[63], [64], [65]
D0066		Amiodarone	C25H29I2NO3	2157	Moderate		Inter Info	[72], [54], [73]
D0120		Atorvastatin	C33H35FN2O5	60823	Moderate		Inter Info	[72], [54], [73]
D0126		Auranofin	C20H34AuO9PS	24199313	Moderate		Inter Info	[72], [54], [73]
D0127		Aurothioglucose	C6H11AuO5S	454937	Moderate		Inter Info	[72], [54], [73]
D0162		Benznidazole	C12H12N4O3	31593	Moderate		Inter Info	[72], [54], [73]
D0199		Brentuximab vedotin	NA	NA	Moderate		Inter Info	[72], [81], [82]
D0227		Cabazitaxel	C45H57NO14	9854073	Moderate		Inter Info	[72], [54], [73]
D0261		Carfilzomib	C40H57N5O7	11556711	Moderate		Inter Info	[72], [54], [73]
D0380		Colchicine	C22H25NO6	6167	Moderate		Inter Info	[72], [54], [73]
D0393		Crizotinib	C21H22Cl2FN5O	11626560	Moderate		Inter Info	[72], [54], [73]
D0496		Diiodohydroxyquinoline	C9H5I2NO	3728	Moderate		Inter Info	[72], [54], [73]
D0501		Dinutuximab	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0511		Docetaxel	C43H53NO14	148124	Moderate		Inter Info	[72], [54], [73]
D0560		Elotuzumab	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0571		Enfortumab vedotin	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0594		Eribulin	C40H59NO11	11354606	Moderate		Inter Info	[72], [54], [73]
D0628		Etravirine	C20H15BrN6O	193962	Moderate		Inter Info	[72], [54], [73]
D0669		Fludarabine	C10H12FN5O4	657237	Moderate		Inter Info	[72], [54], [73]
D0686		Fluvastatin	C24H26FNO4	446155	Moderate		Inter Info	[72], [54], [73]
D0770		Hydralazine	C8H8N4	3637	Moderate		Inter Info	[72], [54], [73]
D0841		Ipilimumab	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0873		Ixabepilone	C27H42N2O5S	6445540	Moderate		Inter Info	[72], [54], [73]
D0874		Ixazomib	C14H19BCl2N2O4	25183872	Moderate		Inter Info	[72], [54], [73]
D0918		Levodopa	C9H11NO4	6047	Moderate		Inter Info	[72], [54], [73]
D1113		Naxitamab	NA	NA	Moderate		Inter Info	[72], [54], [73]
D1118		Nelarabine	C11H15N5O5	3011155	Moderate		Inter Info	[72], [54], [73]
D1212		Paclitaxel	C47H51NO14	36314	Moderate		Inter Info	[72], [54], [73]
D1213		Paclitaxel (protein-bound)	C47H51NO14	36314	Moderate		Inter Info	[72], [54], [73]
D1301		Pitavastatin	C25H24FNO4	5282452	Moderate		Inter Info	[72], [54], [73]
D1306		Polatuzumab vedotin	NA	NA	Moderate		Inter Info	[72], [54], [73]
D1312		Pomalidomide	C13H11N3O4	134780	Moderate		Inter Info	[72], [54], [73]
D1430		Rosuvastatin	C22H28FN3O6S	446157	Moderate		Inter Info	[72], [54], [73]
D1452		Secnidazole	C7H11N3O3	71815	Moderate		Inter Info	[72], [54], [73]
D1479		Sodium aurothiomalate	C4H3AuNa2O4S	22318	Moderate		Inter Info	[72], [54], [73]
D1543		Telbivudine	C10H14N2O5	159269	Moderate		Inter Info	[72], [54], [73]
D1599		Tocilizumab	NA	NA	Moderate		Inter Info	[72], [54], [73]
D1615		Trabectedin	C39H43N3O11S	108150	Moderate		Inter Info	[72], [54], [73]
D1623		Trastuzumab emtansine	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0303		Cerivastatin	C26H34FNO5	446156	Moderate		Inter Info	[72], [54], [73]
D0313		Chloramphenicol	C11H12Cl2N2O5	5959	Moderate		Inter Info	[72], [54], [73]
D0320		Chloroquine	C18H26ClN3	2719	Moderate		Inter Info	[72], [54], [73]
D0344		Cisplatin	Cl2H6N2Pt	5702198	Moderate		Inter Info	[72], [54], [73]
D0419		Dapsone	C12H12N2O2S	2955	Moderate		Inter Info	[72], [54], [73]
D0483		Didanosine	C10H12N4O3	135398739	Moderate		Inter Info	[72], [54], [73]
D0509		Disulfiram	C10H20N2S4	3117	Moderate		Inter Info	[72], [54], [73]
D0616		Ethambutol	C10H24N2O2	14052	Moderate		Inter Info	[72], [54], [73]
D1731		Ethionamide	C8H10N2S	2761171	Moderate		Inter Info	[72], [54], [73]
D0821		Interferon alfa-2a, Recombinant	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0822		Interferon alfa-2b	C16H17Cl3I2N3NaO5S	71306834	Moderate		Inter Info	[72], [54], [73]
D0824		Interferon alfa-n1	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0823		Interferon alfacon-1	NA	NA	Moderate		Inter Info	[72], [54], [73]
D0933		Linezolid	C16H20FN3O4	441401	Moderate		Inter Info	[72], [54], [73]
D0956		Lovastatin	C24H36O5	53232	Moderate		Inter Info	[72], [54], [73]
D1051		Metronidazole	C6H9N3O3	4173	Moderate		Inter Info	[72], [54], [73]
D1145		Nitrofurantoin	C8H6N4O5	6604200	Moderate		Inter Info	[72], [54], [73]
D1193		Oxaliplatin	C8H14N2O4Pt	9887053	Moderate		Inter Info	[72], [54], [73]
D1237		Peginterferon alfa-2a	NA	NA	Moderate		Inter Info	[72], [54], [73]
D1238		Peginterferon alfa-2b	NA	NA	Moderate		Inter Info	[72], [54], [73]
D1329		Pravastatin	C23H36O7	54687	Moderate		Inter Info	[72], [54], [73]
D1473		Simvastatin	C25H38O5	54454	Moderate		Inter Info	[72], [54], [73]
D1504		Stavudine	C10H12N2O4	18283	Moderate		Inter Info	[72], [54], [73]
D1551		Teniposide	C32H32O13S	452548	Moderate		Inter Info	[72], [54], [73]
D1587		Tinidazole	C8H13N3O4S	5479	Moderate		Inter Info	[72], [54], [73]
D1697		Vinblastine	C46H58N4O9	13342	Moderate		Inter Info	[72], [54], [73]
D1698		Vincristine	C46H56N4O10	5978	Moderate		Inter Info	[72], [54], [73]
D1699		Vincristine (liposome)	C46H56N4O10	5978	Moderate		Inter Info	[72], [54], [73]
D1700		Vinorelbine	C45H54N4O8	5311497	Moderate		Inter Info	[72], [54], [73]
D1714		Zafirlukast	C31H33N3O6S	5717	Moderate		Inter Info	[72], [54], [73]
D1715		Zalcitabine	C9H13N3O3	24066	Moderate		Inter Info	[63], [123]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[91]
Pharmacodynamic antagonistic effects
	Antagonize the effect of vaccine/toxoid					Drug Num: 22
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1744		Bacillus calmette-guerin substrain tice live antigen	NA	NA	Major		Inter Info	[7], [8], [9]
D1839		Measles virus vaccine live attenuated	NA	NA	Major		Inter Info	[7], [8], [9]
D1849		Mumps virus strain B level jeryl lynn live antigen	NA	NA	Major		Inter Info	[7], [8], [9]
D1881		Rotavirus vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D1882		Rubella virus vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D1890		Smallpox (Vaccinia) Vaccine, Live	NA	NA	Major		Inter Info	[22], [10], [23]
D1914		Typhoid vaccine (live)	NA	NA	Major		Inter Info	[7], [8], [9]
D1920		Varicella Zoster Vaccine (Recombinant)	NA	NA	Major		Inter Info	[7], [8], [9]
D1922		Yellow Fever Vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D0089		Anthrax vaccine	NA	NA	Moderate		Inter Info	[22], [76], [77]
D0366		Clostridium tetani toxoid antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[22], [76], [77]
D0755		Hepatitis A Vaccine	NA	NA	Moderate		Inter Info	[22], [76], [77]
D0756		Hepatitis B Vaccine (Recombinant)	NA	NA	Moderate		Inter Info	[22], [76], [77]
D0767		Human papillomavirus type 11 L1 capsid protein antigen	NA	NA	Moderate		Inter Info	[22], [76], [77]
D0803		Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)	NA	NA	Moderate		Inter Info	[22], [76], [77]
D0804		Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[22], [76], [77]
D0999		Meningococcal polysaccharide vaccine group C	NA	NA	Moderate		Inter Info	[22], [76], [77]
D1259		Pfizer-BioNTech Covid-19 Vaccine	NA	NA	Moderate		Inter Info	[96], [22], [10], [97], [98], [99], [76], [100], [101], [102], [77]
D1307		Poliovirus type 1 antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[22], [76], [77]
D1662		Typhoid vaccine (inactivated)	NA	NA	Moderate		Inter Info	[22], [76], [77]
D1692		Vibrio cholerae CVD 103-HgR strain live antigen	NA	NA	Moderate		Inter Info	[22], [76], [77]
D1838		Lyme disease vaccine (recombinant OspA)	NA	NA	Moderate		Inter Info	[118]
	Antagonize the effect of probiotics					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1749		Bifidobacterium longum infantis	NA	NA	Moderate		Inter Info	[78], [79], [80]
D1827		Lactobacillus acidophilus	NA	NA	Moderate		Inter Info	[78], [79], [80]
	Diminish the response to diagnostic skin test antigens					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1755		Candida albicans	C29H27N2O12P	118855431	Moderate		Inter Info	[83], [84], [85]
D1765		Coccidioides immitis spherule	NA	NA	Moderate		Inter Info	[83], [84], [85]
D1912		Trichophyton mentagrophytes	NA	NA	Moderate		Inter Info	[83], [84], [85]
D1913		Tuberculin purified protein derivative	NA	NA	Moderate		Inter Info	[83], [84], [85]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1497		Sorafenib	C21H16ClF3N4O3	216239	Major		Inter Info	[51], [52], [53]
D0659		Filgrastim	NA	NA	Moderate		Inter Info	[115], [116], [117]
D1235		Pegfilgrastim	C27H46N4O19	70683024	Moderate		Inter Info	[120], [121]
D1446		Sargramostim	NA	NA	Moderate		Inter Info	[115], [116], [117]

References
1	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
2	Product Information. Enbrel (etanercept). Wyeth-Ayerst Laboratories, Philadelphia, PA.
3	Product Information. Humira (adalimumab). Abbott Pharmaceutical, Abbott Park, IL.
4	Product Information. Remicade (infliximab). Centocor Inc, Malvern, PA.
5	Product Information. Simponi (golimumab). Centocor Inc, Malvern, PA.
6	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. ".
7	Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998).
8	Product Information. Attenuvax (measles virus vaccine, live, attenuated). Merck &amp Co, Inc, West Point, PA.
9	Product Information. YF-Vax (yellow fever vaccine). sanofi pasteur, Swiftwater, PA.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	Product Information. Olumiant (baricitinib). Lilly, Eli and Company, Indianapolis, IN.
13	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
14	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
15	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
16	Product Information. Tegsedi (inotersen). Akcea Therapeutics, Cambridge, MA.
17	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
18	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
19	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
20	Product Information. Quadramet (samarium sm 153 lexidronam) Berlex Laboratories, Richmond, CA.
21	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
22	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
23	Product Information. Dryvax (smallpox vaccine). Wyeth-Ayerst Laboratories, Philadelphia, PA.
24	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
25	Bennett CL, Schumock GT, Desai AA, et al "Thalidomide-associated deep vein thrombosis and pulmonary embolism." Am J Med 113 (2002): 603-6. [PMID: 12459408]
26	Cavo M, Zamagni E, Cellini C, et al. "Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy." Blood 100 (2002): 2272-3. [PMID: 12229885]
27	Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A "Thalidomide and venous thrombosis." Ann Intern Med 136 (2002): 711. [PMID: 11992318]
28	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
29	Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
30	Lee CK, Barlogie B, Munshi N, et al "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma." J Clin Oncol 21 (2003): 2732-9. [PMID: 12860952]
31	Osman K, Comenzo R, Rajkumar SV "Deep venous thrombosis and thalidomide therapy for multiple myeloma." N Engl J Med 344 (2001): 1951-2. [PMID: 11419443]
32	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
33	Rajkumar SV, Hayman S, Gertz MA, et al. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." J Clin Oncol 20 (2002): 4319-23. [PMID: 12409330]
34	Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J "Thromboembolic events during treatment with thalidomide." Blood 99 (2002): 4247-8. [PMID: 12043695]
35	Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma." J Clin Oncol 21 (2003): 16-9. [PMID: 12506164]
36	Zangari M, Anaissie E, Barlogie B, et al "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy." Blood 98 (2001): 1614-5. [PMID: 11520815]
37	Zangari M, Barlogie B, Anaissie E, et al "Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation." Br J Haematol 126 (2004): 715-21. [PMID: 15327525]
38	Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
39	Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." Cancer 95 (2002): 1629-36. [PMID: 12365009]
40	Product Information. Thiotepa (thiotepa). Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
41	Product Information. Xeljanz (tofacitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42	Chou TC, Motzer RJ, Tong Y, Bosl GJ "Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design." J Natl Cancer Inst 86 (1994): 1517-24.[PMID: 7932806]
43	Product Information. Hycamtin (topotecan). SmithKline Beecham, Philadelphia, PA.
44	Rowinsky EK, Kaufmann SH, Baker SD, et al. "Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence."?J Clin Oncol. 1996;14(12):3074-3084.[PMID: 8955652]
45	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
46	Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
47	Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.
48	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
49	Canadian Pharmacists Association "e-CPS."
50	Product Information. Tysabri (natalizumab). Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.
51	Flaherty KT, Schiller J, Schuchter, et al "A phrase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel." Clin Cancer Res 14 (2008): 4836-42. [PMID: 18676756]
52	Polcher M, Eckhardt M, Coch C, et al. "Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer." Cancer Chemother Pharmacol 66 (2010): 203-7.[PMID: 20204367]
53	Scagliotti G, Novello S, von Pawel J, et al. "Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer." J Clin Oncol 28 (2010): 1835-42.[PMID: 20212250]
54	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
55	Product Information. Fluorouracil injection (fluorouracil). Roche Laboratories, Nutley, NJ.
56	Product Information. Amevive (alefacept). Biogen, Cambridge, MA.
57	Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
58	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
59	Product Information. Paraplatin (carboplatin). Bristol-Myers Squibb, Princeton, NJ.
60	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
61	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.
62	Product Information. Kineret (anakinra). Amgen, Thousand Oaks, CA.
63	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
64	Cavaletti G, Jakubowiak AJ "Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies." Leuk Lymphoma 51 (2010): 1178-87. [PMID: 20497001]
65	Product Information. Velcade (bortezomib). Millennium Pharmaceuticals Inc, Cambridge, MA.
66	Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O "Understanding platinum-induced ototoxicity." Trends Pharmacol Sci 34 (2013): 458-69. [PMID: 23769626]
67	Parsons SK, Neault MW, Lehmann, et al "Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma." Bone Marrow Transplant 22 (1998): 669-74. [PMID: 9818694]
68	Product Information. Edecrin (ethacrynic acid). Merck & Co, Inc, West Point, PA.
69	Brock PR, Knight KR, Freyer DR, et al. "Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale." J Clin Oncol 30 (2012): 2408-17. [PMID: 22547603]
70	Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7. [PMID: 25652747]
71	Product Information. Vancocin (vancomycin). Lilly, Eli and Company, Indianapolis, IN.
72	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
73	Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online."
74	Le AT, Hasson NK, Lum BL "Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy." Ann Pharmacother 31 (1997): 1006-8. [PMID: 9296241]
75	Seifter EJ, Brooks BJ, Urba WJ "Possible interactions between warfarin and antineoplastic drugs." Cancer Treat Rep 69 (1985): 244-5. [PMID: 3971397]
76	Product Information. Imovax Rabies (rabies vaccine). sanofi pasteur, Swiftwater, PA.
77	Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.".
78	Borriello SP, Hammes WP, Holzapfel W, et.al "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003): 775-80. [PMID: 12627362]
79	Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998): 887-8. [PMID: 10052559]
80	Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002): 1155-60. [PMID: 12410474]
81	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
82	Product Information. Danyelza (naxitamab). Y-mAbs Therapeutics, New York, NY.
83	Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative). Connaught Laboratories Ltd, Toronto, ON.
84	Product Information. Candin (candida albicans extract). Nielsen Biosciences Inc, San Diego, CA.
85	Product Information. Spherulin (coccidioidin skin test). ALK Laboratories Inc, Wallingford, CT.
86	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
87	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
88	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
89	Product Information. Cytovene (ganciclovir). Genentech, South San Francisco, CA.
90	Product Information. Valcyte (valganciclovir) Roche Laboratories, Nutley, NJ.
91	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
92	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
93	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
94	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
95	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
96	CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence." .
97	Product Information. Biothrax (anthrax vaccine adsorbed). Emergent BioSolutions Inc., Lansing, MI.
98	Product Information. Fluzone Influenza Vaccine (influenza virus vaccine). Connaught, Swiftwater, PA.
99	Product Information. Havrix (hepatitis A vaccine). SmithKline Beecham, Philadelphia, PA.
100	Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated). GlaxoSmithKline, Research Triangle Park, NC.
101	Product Information. Omnihib (haemophilus b conjugate vaccine). SmithKline Beecham, Philadelphia, PA.
102	CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.".
103	Product Information. Xofigo (radium Ra 223 dichloride). Bayer Pharmaceutical Inc, West Haven, CT.
104	European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
105	Gilead Sciences, Inc "About Remdesivir.".
106	US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)".
107	Product Information. Daxas (roflumilast). Nycomed Inc, Princeton, NJ.
108	AnazaoHealth Corporation "P32 Sodium Phosphate."
109	Multum Information Services, Inc. Expert Review Panel.
110	Product Information. Stelara (ustekinumab). Centocor Inc, Malvern, PA.
111	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
112	Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36. [PMID: 14769198]
113	Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
114	Product Information. Edecrin (ethacrynic acid). Merck &amp Co, Inc, West Point, PA.
115	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
116	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
117	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.
118	Shen AK, Mead PS, Beard CB. The Lyme disease vaccine--a public health perspective. Clin Infect Dis. 2011;52 Suppl 3:s247-s252. [PMID: 21217171]
119	Product Information. Kepivance (palifermin). Shire US Inc, Florence, KY.
120	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
121	Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA.
122	Product Information. Valtrex (valacyclovir). Glaxo Wellcome, Research Triangle Park, NC.
123	Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.
124	Product Information. Retrovir (zidovudine). Glaxo Wellcome, Research Triangle Park, NC.
125	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence